Recorded live at the 2019 San Antonio Breast Cancer Symposium, Dr. Matt Birnholz sat down with Dr. Nadine Tung, Associate Professor of Medicine at Harvard Medical School and Director of the Cancer Risk and Prevention Program at Beth Israel Deaconess Medical Center, to talk about her presentation on genetic testing for hereditary breast cancer.

Considering there’s little known about the breast microenvironment during pregnancy and whether this plays into future breast cancer risk, Dr. Lauren Nye's team examined whether omega 3 supplements as potential non-teratogenic chemoprevention agents could accentuate the protective changes on breast cancer risk that occur with hormonal fluctuations during pregnancy. And Dr. Matt Birnholz was there at the 2019 San Antonio Breast Cancer Symposium to catch up with Dr. Nye about this study.

Though statins have long been used for the treatment of hypercholesterolemia, growing evidence suggests they may also have a role in lowering the risk of breast cancer development. But how they potentially do this and whether all statins are equal to that task was the focus of Dr. Matt Birnholz’s discussion with Dr. Stephen Hiscox at the 2019 San Antonio Breast Cancer Symposium.

Much of the focus on endocrine therapy tends to be around future directions and what new treatments are going to accelerate care for breast cancer patients. But oncologists need to take stock of how physically and financially costly it can be, as Dr. Dawn Hershman explains to Dr. Matt Birnholz at the 2019 San Antonio Breast Cancer Symposium.

Vaccine hesitancy refers to a delay in acceptance or refusal of vaccines, despite their availability and an overall recommendation for them. To help reinforce the importance of vaccinations, this activity describes the threat vaccine hesitancy poses to public health and the relationship between HPV vaccination and protection from cervical and oropharyngeal cancers.

Tune in as Dr. Jen Simmons is joined by Dr. Susan Domcheck, who debunks the common misconception that men don’t have to worry about the BCRA mutation and dives into the explorations of the Before Study.

Anytime the topic of genetic testing comes up in the context of breast and ovarian cancers, one question that undoubtedly arises is: who exactly should be tested? That’s the FAQ Dr. Susan Domchek, Director of the McDonald Women’s Cancer Risk Evaluation Center at the Hospital of the University of Pennsylvania, answers.

At the 2019 Lynn Sage Breast Cancer Symposium in Chicago, Illinois, Dr. Matt Birnholz caught up with Kelly Scheu, a nurse practitioner specializing in breast oncology at the University of Michigan, who shared how her spirituality and medical expertise of 27 years in the oncology field blend to enhance breast cancer care.

Recorded live at the 2019 Lynn Sage Breast Cancer Symposium in Chicago, Illinois, Dr. Jonathan Strauss, an Associate Professor of Radiation Oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, shares key strategies for delivering targeted radiotherapy to avoid damaging associated tissues.

Joining Dr. Matt Birnholz at the 2019 Lynn Sage Breast Cancer Symposium in Chicago, Illinois, is Dr. Jonathan Strauss to discuss the talks he’s given at this year’s conference on the evolution of radiation oncology as a field, challenging breast cancer cases, and emerging factors that support the emission of radiotherapy in invasive cancers.